Stryker (NYSE:SYK) Given “Buy” Rating at BTIG Research

BTIG Research reissued their buy rating on shares of Stryker (NYSE:SYK) in a report released on Tuesday morning,Benzinga reports. The brokerage currently has a $397.00 price objective on the medical technology company’s stock.

Other research analysts also recently issued research reports about the stock. Piper Sandler reissued an “overweight” rating on shares of Stryker in a report on Tuesday, January 27th. Citigroup dropped their price objective on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. Citizens Jmp raised shares of Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 price objective for the company in a report on Friday, December 19th. Barclays reissued an “overweight” rating and set a $469.00 price objective on shares of Stryker in a report on Monday, February 2nd. Finally, UBS Group dropped their price objective on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a report on Tuesday, March 17th. Fifteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $421.74.

Stryker Stock Down 0.4%

SYK opened at $345.77 on Tuesday. The firm has a 50-day simple moving average of $354.15 and a two-hundred day simple moving average of $360.07. Stryker has a 52 week low of $319.32 and a 52 week high of $404.87. The company has a market capitalization of $132.42 billion, a PE ratio of 41.16, a price-to-earnings-growth ratio of 2.03 and a beta of 0.92. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, beating the consensus estimate of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The business had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.12 billion. During the same quarter in the prior year, the firm earned $4.01 EPS. The business’s revenue was up 11.4% on a year-over-year basis. Analysts forecast that Stryker will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Tuesday, March 31st. Stryker’s dividend payout ratio is currently 41.90%.

Insider Activity

In other news, Director Ronda E. Stryker sold 250,000 shares of the company’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the sale, the director directly owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This represents a 9.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.60% of the company’s stock.

Institutional Trading of Stryker

Several hedge funds have recently made changes to their positions in the business. J. Derek Lewis & Associates Inc. purchased a new stake in shares of Stryker during the 4th quarter valued at about $234,000. Stance Capital LLC raised its position in Stryker by 4.8% in the 4th quarter. Stance Capital LLC now owns 12,517 shares of the medical technology company’s stock worth $4,399,000 after purchasing an additional 569 shares during the period. Rockefeller Capital Management L.P. raised its position in Stryker by 13.3% in the 4th quarter. Rockefeller Capital Management L.P. now owns 85,579 shares of the medical technology company’s stock worth $30,079,000 after purchasing an additional 10,037 shares during the period. World Investment Advisors raised its position in Stryker by 0.7% in the 4th quarter. World Investment Advisors now owns 10,890 shares of the medical technology company’s stock worth $3,828,000 after purchasing an additional 71 shares during the period. Finally, Corient Private Wealth LLC raised its position in Stryker by 3.3% in the 4th quarter. Corient Private Wealth LLC now owns 981,354 shares of the medical technology company’s stock worth $345,023,000 after purchasing an additional 31,361 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

More Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Strategic acquisition — Stryker signed a definitive agreement to buy Amplitude Vascular Systems to add next‑generation IVL for calcified peripheral arterial disease, expanding its peripheral vascular offering and addressable market; this is a tuck‑in that could drive product revenue and market share in vascular interventions. Stryker signs definitive agreement to acquire Amplitude Vascular Systems
• Positive Sentiment: New analyst coverage — Leerink Partners initiated coverage with an “outperform” rating and a $410 price target, signaling confidence in Stryker’s growth trajectory and the strategic rationale for the AVS deal. Leerink Partners initiates coverage of Stryker
• Positive Sentiment: BTIG reiteration — BTIG reaffirmed a “buy” rating and set a $397 price target, adding another institutional vote of confidence that implies meaningful upside from current levels. BTIG reaffirms buy on Stryker
• Neutral Sentiment: Widespread press coverage — Multiple outlets (Seeking Alpha, MassDevice, Zacks, FinanzNachrichten, etc.) have reported the acquisition and deal details; this broad reporting can increase visibility but largely reiterates the same strategic points. Stryker acquiring Amplitude Vascular Systems — Seeking Alpha
• Negative Sentiment: Near‑term technical/market pressure — SYK is trading below its 50‑ and 200‑day moving averages and saw higher-than-average volume today; despite the strategic positives, technical weakness or broader market/sector rotation may be driving the intra‑day decline.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.